Gender dimorphism in regulation of plasma proteins in streptozotocin-induced diabetic rats

Proteomics

Volumn 13, Issue 16, 2013, Pages 2482-2494

  Choi, Jung Won ^a   Aseer, Kanikkai Raja ^a   Chaudhari, Harmesh N ^a   Mukherjee, Rajib ^a   Choi, Minji ^a   Yun, Jong Won ^a  

^a Daegu University   (South Korea)

Author keywords

2DE; Diabetes; Gender differences; Plasma proteome; Streptozotocin

Indexed keywords

3 HYDROXYANTHRANILATE 3,4 DIOXYGENASE; APOLIPOPROTEIN E; BETA2 GLYCOPROTEIN 1; FETUIN B; GLUCOSE; INSULIN; OROSOMUCOID; PLASMA PROTEIN; SERUM AMYLOID P; SEX HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; FEMALE; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN SYNTHESIS REGULATION; PROTEOMICS; RAT; SEX DIFFERENCE; STREPTOZOCIN DIABETES;

EID: 84881493512     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201200529     Document Type: Article

References (62)

1. Maahs, D. M., West, N. A., Lawrence, J. M., Mayer-Davis, E. J., Epidemiology of type 1 diabetes. Endocrinol. Metab. Clin. North Am. 2010, 39, 481-497.
2. Rossini, A. A., Like, A. A., Chick, W. L., Appel, M. C., Cahill, G. F., Jr., Studies of streptozotocin-induced insulitis and diabetes. Proc. Natl. Acad. Sci. U.S.A. 1977, 74, 2485-2489.
3. Szkudelski, T., The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol. Res. 2001, 50, 537-546.
4. Wei, M., Ong, L., Smith, M. T., Ross, F. B. et al., The streptozotocin-diabetic rat as a model of the chronic complications of human diabetes. Heart Lung Circ. 2003, 12, 44-50.
5. Korc, M., Diabetes mellitus in the era of proteomics. Mol. Cell. Proteomics 2003, 2, 399-404.
6. Scott, E. M., Carter, A. M., Findlay, J. B., The application of proteomics to diabetes. Diab. Vasc. Dis. Res. 2005, 2, 54-60.
7. Sundsten, T., Ortsater, H., Proteomics in diabetes research. Mol. Cell. Endocrinol. 2009, 297, 93-103.
8. Chen, C. C., Lu, Y. C., Chen, Y. W., Lee, W. L. et al., Hemopexin is up-regulated in plasma from type 1 diabetes mellitus patients: Role of glucose-induced ROS. J. Proteomics 2012, 75, 3760-3777.
9. Anderson, N. L., Anderson, N. G., The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell. Proteomics 2002, 1, 845-867.
10. Anderson, N. L., The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin. Chem. 2010, 56, 177-185.
11. Purohit, S., Podolsky, R., Schatz, D., Muir, A. et al., Assessing the utility of SELDI-TOF and model averaging for serum proteomic biomarker discovery. Proteomics 2006, 6, 6405-6415.
12. Overgaard, A. J., Hansen, H. G., Lajer, M., Pedersen, L. et al., Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy. Proteome Sci. 2010, 8, 4-14.
13. Sundsten, T., Eberhardson, M., Goransson, M., Bergsten, P., The use of proteomics in identifying differentially expressed serum proteins in humans with type 2 diabetes. Proteome Sci. 2006, 4, 22-31.
14. Kim, H. J., Cho, E. H., Yoo, J. H., Kim, P. K. et al., Proteome analysis of serum from type 2 diabetics with nephropathy. J. Proteome Res. 2007, 6, 735-743.
15. Sundsten, T., Zethelius, B., Berne, C., Bergsten, P., Plasma proteome changes in subjects with Type 2 diabetes mellitus with a low or high early insulin response. Clin. Sci. (Lond.) 2008, 114, 499-507.
16. Zillikens, M. C., Yazdanpanah, M., Pardo, L. M., Rivadeneira, F. et al., Sex-specific genetic effects influence variation in body composition. Diabetologia 2008, 51, 2233-2241.
17. Kautzky-Willer, A., Handisurya, A., Metabolic diseases and associated complications: sex and gender matter! Eur. J. Clin. Invest. 2009, 39, 631-648.
18. Gale, E. A., Gillespie, K. M., Diabetes and gender. Diabetologia 2001, 44, 3-15.
19. Legato, M. J., Gelzer, A., Goland, R., Ebner, S. A. et al., Gender-specific care of the patient with diabetes: review and recommendations. Gend. Med. 2006, 3, 131-158.
20. Szalat, A., Raz, I., Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women. Diabetes Obes. Metab. 2008, 10, 1135-1156.
21. Perreault, L., Ma, Y., Dagogo-Jack, S., Horton, E. et al., Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care 2008, 31, 1416-1421.
22. Choi, D. K., Oh, T. S., Choi, J. W., Mukherjee, R. et al., Gender difference in proteome of brown adipose tissues between male and female rats exposed to a high fat diet. Cell. Physiol. Biochem. 2011, 28, 933-948.
23. Oh, T. S., Choi, J. W., Choi, D. K., Mukherjee, R. et al., Gender dimorphism in skeletal muscle proteome between lean and diet-induced obese rats. Cell. Physiol. Biochem. 2011, 28, 981-996.
24. Choi, J. W., Liu, H., Choi, D. K., Oh, T. S. et al., Profiling of gender-specific rat plasma proteins associated with susceptibility or resistance to diet-induced obesity. J. Proteomics 2012, 75, 1386-1400.
25. Liu, H., Choi, J. W., Yun, J. W., Gender differences in rat plasma proteome in response to high-fat diet. Proteomics 2012, 12, 269-283.
26. Mukherjee, R., Choi, J. W., Choi, D. K., Oh, T. S. et al., Gender-dependent protein expression in white adipose tissues of lean and obese rats fed a high fat diet. Cell. Physiol. Biochem. 2012, 29, 617-634.
27. Wang, X., Choi, J. W., Oh, T. S., Choi, D. K. et al., Comparative hepatic proteome analysis between lean and obese rats fed a high-fat diet reveals the existence of gender differences. Proteomics 2012, 12, 284-299.
28. Le May, C., Chu, K., Hu, M., Ortega, C. S. et al., Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 9232-9237.
29. Vital, P., Larrieta, E., Hiriart, M., Sexual dimorphism in insulin sensitivity and susceptibility to develop diabetes in rats. J. Endocrinol. 2006, 190, 425-432.
30. Choi, M., Choi, J. W., Chaudhari, H. N., Aseer, K. R. et al., Gender-dimorphic regulation of skeletal muscle proteins in streptozotocin-induced diabetic rats. Cell. Physiol. Biochem. 2013, 31, 408-420.
31. Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem 1976, 72, 248-254.
32. Shevchenko, A., Wilm, M., Vorm, O., Mann, M., Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal. Chem. 1996, 68, 850-858.
33. Kim, S. W., Hwang, H. J., Kim, H. M., Lee, M. C. et al., Effect of fungal polysaccharides on the modulation of plasma proteins in streptozotocin-induced diabetic rats. Proteomics 2006, 6, 5291-5302.
34. Gao, J., He, J., Shi, X., Stefanovic-Racic, M. et al., Sex-specific effect of estrogen sulfotransferase on mouse models of type 2 diabetes. Diabetes 2012, 61, 1543-1551.
35. Mauvais-Jarvis, F., Estrogen sulfotransferase: intracrinology meets metabolic diseases. Diabetes 2012, 61, 1353-1354.
36. Davidsson, P., Hulthe, J., Fagerberg, B., Camejo, G., Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 156-163.
37. Wang, F., Kohan, A. B., Kindel, T. L., Corbin, K. L. et al., Apolipoprotein A-IV improves glucose homeostasis by enhancing insulin secretion. Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 9641-9646.
38. Verges, B. L., Vaillant, G., Goux, A., Lagrost, L. et al., Apolipoprotein A-IV levels and phenotype distribution in NIDDM. Diabetes Care 1994, 17, 810-817.
39. Chaudhary, R., Likidlilid, A., Peerapatdit, T., Tresukosol, D. et al., Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery disease. Cardiovasc. Diabetol. 2012, 11, 36-46.
40. van der Ham, R. L., Alizadeh Dehnavi, R., Berbee, J. F., Putter, H. et al., Plasma apolipoprotein CI and CIII levels are associated with increased plasma triglyceride levels and decreased fat mass in men with the metabolic syndrome. Diabetes Care 2009, 32, 184-186.
41. Ooi, E. M., Watts, G. F., Chan, D. C., Nielsen, L. B. et al., Association of apolipoprotein M with high-density lipoprotein kinetics in overweight-obese men. Atherosclerosis 2010, 210, 326-330.
42. Basu, T. K., Basualdo, C., Vitamin A homeostasis and diabetes mellitus. Nutrition 1997, 13, 804-806.
43. Baena, R. M., Campoy, C., Bayes, R., Blanca, E. et al., Vitamin A, retinol binding protein and lipids in type 1 diabetes mellitus. Eur. J. Clin. Nutr. 2002, 56, 44-50.
44. Refai, E., Dekki, N., Yang, S. N., Imreh, G. et al., Transthyretin constitutes a functional component in pancreatic beta-cell stimulus-secretion coupling. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 17020-17025.
45. Blanton, D., Han, Z., Bierschenk, L., Linga-Reddy, M. V. et al., Reduced serum vitamin D-binding protein levels are associated with type 1 diabetes. Diabetes 2011, 60, 2566-2570.
46. Stefan, N., Hennige, A. M., Staiger, H., Machann, J. et al., Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 2006, 29, 853-857.
47. Mori, K., Emoto, M., Yokoyama, H., Araki, T. et al., Association of serum fetuin-A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care 2006, 29, 468.
48. Stefan, N., Fritsche, A., Weikert, C., Boeing, H. et al., Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 2008, 57, 2762-2767.
49. Olivier, E., Soury, E., Ruminy, P., Husson, A. et al., Fetuin-B, a second member of the fetuin family in mammals. Biochem. J. 2000, 350, 589-597.
50. Miller, L. L., Treat, D. E., Fridd, B., Wemett, D., Effects of streptozotocin diabetes in the rat on blood levels of ten specific plasma proteins and on their net biosynthesis by the isolated perfused liver. Hepatology 1990, 11, 635-645.
51. Tolosano, E., Altruda, F., Hemopexin: structure, function, and regulation. DNA Cell. Biol. 2002, 21, 297-306.
52. Ahmed, F. N., Naqvi, F. N., Shafiq, F., Lipid peroxidation and serum antioxidant enzymes in patients with type 2 diabetes mellitus. Ann. N. Y. Acad. Sci. 2006, 1084, 481-489.
53. Cunningham, J., Leffell, M., Mearkle, P., Harmatz, P., Elevated plasma ceruloplasmin in insulin-dependent diabetes mellitus: evidence for increased oxidative stress as a variable complication. Metabolism 1995, 44, 996-999.
54. Targher, G., Bertolini, L., Zoppini, G., Zenari, L., Falezza, G., Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy. Diabet. Med. 2005, 22, 999-1004.
55. Fournier, T., Medjoubi, N. N., Porquet, D., Alpha-1-acid glycoprotein. Biochim. Biophys. Acta. 2000, 1482, 157-171.
56. Engstrom, G., Hedblad, B., Eriksson, K. F., Janzon, L., Lindgarde, F., Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 2005, 54, 570-575.
57. Weyer, C., Tataranni, P. A., Pratley, R. E., Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration. Diabetes Care 2000, 23, 779-785.
58. Van Harmelen, V., Reynisdottir, S., Cianflone, K., Degerman, E. et al., Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J. Biol. Chem. 1999, 274, 18243-18251.
59. Van Greevenbroek, M. M., Vermeulen, V. M., De Bruin, T. W., Identification of novel molecular candidates for fatty liver in the hyperlipidemic mouse model, HcB19. J. Lipid Res. 2004, 45, 1148-1154.
60. Laz, E. V., Wiwi, C. A., Waxman, D. J., Sexual dimorphism of rat liver nuclear proteins: regulatory role of growth hormone. Mol. Cell. Proteomics 2004, 3, 1170-1180.
61. Garg, A., Grundy, S. M., Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990, 264, 723-726.
62. Stettler, C., Witt, N., Tapp, R. J., Thom, S. et al., Serum amyloid A, C-reactive protein, and retinal microvascular changes in hypertensive diabetic and nondiabetic individuals: an Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) substudy. Diabetes Care 2009, 32, 1098-1100.